Funding was co-led by B Capital and U.S. Venture Partners, according to a news release. The money will support development of personalized cervical spinal fusion implants and commercialization of aprevo lumbar fusion devices.
Aprevo has FDA breakthrough device designation for lumbar and cervical patient-specific interbody fusion devices. Carlsmed’s aprevo cervical fusion implant is expected to launch in 2025.
